GSK news live: overbought signals rise — RSI hits 71.02 as price nears resistance

Traders Union
All News
Financial News
GSK rises 0.26% today to $1,761.50

Highlights

GSK plc trades at $1,761.50, gaining 0.26% on the day and holding firmly above its MA-20, MA-50, and MA-200 levels.
GSK expanded treasury holdings beyond 254 million shares after repurchasing 345,500 shares, confirmed a 3.61% dividend yield, and announced an mRNA vaccine collaboration with CureVac.
Technical momentum remains bullish with key indicators on 'Buy,' but RSI at 71.02 and multiple oscillators signal overbought conditions, suggesting sideway consolidation between $1,734.50 and $1,868.00.

Share buybacks and mRNA collaboration fuel stability and growth momentum

GSK has continued its share buyback program with recent purchases totaling 345,500 ordinary shares in two separate transactions, bringing its treasury holdings to over 254 million shares as of October 31, 2025. The company reaffirmed its financial stability with a dividend yield of 3.61% and a payout ratio of 47.40%. GSK also expanded its healthcare portfolio through a collaboration with CureVac to develop mRNA vaccines for infectious diseases.

Diverging oscillators highlight caution amid persistent overbought momentum

Technically, GSK’s price is trading well above all major moving averages, indicating a strong bullish trend. The nearest dynamic support is the Ichimoku Kijun at $1,644.00, with resistance seen near the MA-50 at $1,566.38 and the recent intraday high at $1,781.00. Momentum indicators such as MACD and ADX remain on 'Buy,' while the RSI sits at 71.02 and points to overbought conditions. Other oscillators are mixed — Stoch RSI gives a 'Strong Sell,' CCI is 'Overbought,' and the BBP indicates overbought conditions as well. The Awesome Oscillator supports the uptrend, though divergence among oscillators suggests caution despite moderate volatility and resilience near session highs.

Further gains likely as bullish outlook dominates short-term trading range

Over the next five trading days, GSK is expected to trade within a range of $1,734.50 to $1,868.00. There is a very high probability (over 80%) of a further price increase, as weekly indicators — RSI, ADX, MACD, and MA-50 — all remain bullish. The base case points to sideways consolidation between key support and resistance levels. In a bullish scenario, a break above $1,781.00 may lead toward the $1,868.00 range top, while a drop below $1,744.00 could expose support closer to $1,644.00.

Viktoras Karapetjanc, Traders Union expert, sees GSK plc maintaining a robust technical and fundamental stance, supported by ongoing share buybacks, a solid dividend profile, and recent pipeline expansion. He believes the bullish momentum remains intact across timeframes, with price action well above all major averages and macro sentiment reinforced by management's capital returns. While oscillators warn of short-term overbought conditions, the overall risk-reward favors further gains unless key supports are lost. "A constructive outlook is warranted here — with GSK’s strong fundamentals and positive sentiment, I expect buyers to remain in control as long as the price holds above $1,744.00."

Previously it was noted that technical indicators showed mixed momentum amid cautious sentiment. Buyback activity and investor accumulation were offset by R&D pipeline risks as volatility remained low during a period of price consolidation.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.